Search

Your search keyword '"Bolognese, Leonardo"' showing total 3 results
Start Over Author "Bolognese, Leonardo" Language undetermined
3 results on '"Bolognese, Leonardo"'

1. Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial

Author

Warren J. Cantor, Shaun G. Goodman, Mathieu Kerneis, Frédéric Lapostolle, Jens Flensted Lassen, Gilles Montalescot, Enrico Fabris, Anne Tsatsaris, Robert F. Storey, Leonardo Bolognese, Jurriën M. ten Berg, Uwe Zeymer, Christopher J. Hammett, Béla Merkely, Kurt Huber, Christian W. Hamm, Mohamed Chettibi, Eric Vicaut, Angel Cequier, Abdourahmane Diallo, Magnus Janzon, Arnoud W J van 't Hof, Fabris, Enrico, van 't Hof, Arnoud, Hamm, Christian W, Lapostolle, Frédéric, Lassen, Jens F, Goodman, Shaun G, Ten Berg, Jurriën M, Bolognese, Leonardo, Cequier, Angel, Chettibi, Mohamed, Hammett, Christopher J, Huber, Kurt, Janzon, Magnu, Merkely, Béla, Storey, Robert F, Zeymer, Uwe, Cantor, Warren J, Tsatsaris, Anne, Kerneis, Mathieu, Diallo, Abdourahmane, Vicaut, Eric, Montalescot, Gilles, Cardiologie, RS: CARIM - R2.01 - Clinical atrial fibrillation, MUMC+: MA Med Staf Spec Cardiologie (9), and RS: Carim - H01 Clinical atrial fibrillation

Subjects
Male, prehospital ticagrelor, Ticagrelor, REPERFUSION THERAPY, st segment resolution, medicine.medical_treatment, PREHOSPITAL TICAGRELOR, PRIMARY ANGIOPLASTY, 030204 cardiovascular system & hematology, Coronary Angiography, Critical Care and Intensive Care Medicine, DOUBLE-BLIND, Electrocardiography, 0302 clinical medicine, TO-BALLOON TIME, ST segment, 030212 general & internal medicine, vasodilation, Coronary Vessel, Aspirin, medicine.diagnostic_test, General Medicine, Middle Aged, Coronary Vessels, reperfusion, ST-elevation myocardial infarction, Treatment Outcome, medicine.anatomical_structure, Combination, DELAY, Cardiology, Platelet aggregation inhibitor, Drug Therapy, Combination, Female, Cardiology and Cardiovascular Medicine, ST segment resolution, Human, medicine.drug, medicine.medical_specialty, st-elevation myocardial infarction, delay, ticagrelor, Aged, Coronary Circulation, Double-Blind Method, Humans, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, ST Elevation Myocardial Infarction, Time-to-Treatment, 03 medical and health sciences, Coronary circulation, Reperfusion therapy, Drug Therapy, Internal medicine, medicine, business.industry, MORTALITY, Platelet Aggregation Inhibitor, ELEVATION MYOCARDIAL-INFARCTION, Percutaneous coronary intervention, DIABETES-MELLITUS, business, VASODILATION
Abstract

Background: In the ATLANTIC (Administration of Ticagrelor in the catheterization laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery) trial the early use of aspirin, anticoagulation, and ticagrelor coupled with very short medical contact-to-balloon times represent good indicators of optimal treatment of ST-elevation myocardial infarction and an ideal setting to explore which factors may influence coronary reperfusion beyond a well-established pre-hospital system. Methods: This study sought to evaluate predictors of complete ST-segment resolution after percutaneous coronary intervention in ST-elevation myocardial infarction patients enrolled in the ATLANTIC trial. ST-segment analysis was performed on electrocardiograms recorded at the time of inclusion (pre-hospital electrocardiogram), and one hour after percutaneous coronary intervention (post-percutaneous coronary intervention electrocardiogram) by an independent core laboratory. Complete ST-segment resolution was defined as ≥70% ST-segment resolution. Results: Complete ST-segment resolution occurred post-percutaneous coronary intervention in 54.9% ( n=800/1456) of patients and predicted lower 30-day composite major adverse cardiovascular and cerebrovascular events (odds ratio 0.35, 95% confidence interval 0.19–0.65; pConclusions: This study confirmed that post-percutaneous coronary intervention complete ST-segment resolution is a valid surrogate marker for cardiovascular clinical outcomes. In the current era of ST-elevation myocardial infarction reperfusion, patients’ delay and diabetes mellitus are independent predictors of poor reperfusion and need specific attention in the future.

Published
2017

2. Pravila o sukobu interesa i zahtjevi za prijavljivanjem sukoba interesa u nacionalnim kardiovaskularnim časopisima Europskog kardiološkog društva

Author

Fernando Alfonso, Adam Timmis, Fausto J. Pinto, Giuseppe Ambrosio, Hugo Ector, Piotr Kulakowski, Panos Vardas, null Editors' Network members, Loizos Antoniades, Mansoor Ahmad, Eduard Apetrei, Kaduo Arai, Jean-Yves Artigou, Michael Aschermann, Michael Böhm, Leonardo Bolognese, Raffaele Bugiardini, Ariel Cohen, Istvan Edes, Joseph Elias, Javier Galeano, Eduardo Guarda, Habib Haouala, Magda Heras, Christer Höglund, Kurt Huber, Ivan Hulin, Mario Ivanusa, Rungroj Krittayaphong, Chi-Tai Kuo, Chu-Pak Lau, Victor A. Lyusov, Germanas Marinskis, Manlio F. Márquez, Izet Masic, Luiz Felipe Pinho Moreira, Alexander Mrochek, Rafael G. Oganov, Dimitar Raev, Mamanti Rogava, Olaf Rødevand, Vedat Sansoy, Hiroaki Shimokawa, Valentin A. Shumakov, Carlos Daniel Tajer, Ernst E. van der Wall, Christodoulos Stefanadis, Jørgen Videbæk, Thomas F. Lüscher, Alfonso F, Timmis A, Pinto FJ, Ambrosio G, Ector H, Kulakowski P, Vardas P, Loizos Antoniades L, Ahmad M, Apetrei E, Arai K, Artigou JY, Aschermann M, Böhm M, Bolognese L, Bugiardini R, Cohen A, Edes I, Elias J, Galeano J, Guarda E, Haouala H, Heras M, Höglund C, Huber K, Hulin I, Ivanusa M, Krittayaphong R, Kuo CT, Lau CP, Lyusov VA, Marinskis G, Márquez MF, Masic I, Pinho-Moreira LF, Mrochek A, Oganov RG, Raev D, Rogava M, Rødevand O, Sansoy V, Shimokawa H, Shumakov VA, Tajer CD, van der Wall EE, Stefanadis C, Videbæk J, Lüscher TF, Antoniades L, Moreira LF, Christodoulos Stefanadis EE, Lüscher TF., Alfonso, Fernando, Timmis, Adam, Pinto, Fausto J., Ambrosio, Giuseppe, Ector, Hugo, Kulakowski, Piotr, Vardas, Pano, Antoniades, Loizo, Ahmad, Mansoor, Apetrei, Eduard, Arai, Kaduo, Artigou, Jean-Yve, Aschermann, Michael, Böhm, Michael, Bolognese, Leonardo, Bugiardini, Raffaele, Cohen, Ariel, Edes, Istvan, Elias, Joseph, Galeano, Javier, Guarda, Eduardo, Haouala, Habib, Heras, Magda, Höglund, Christer, Huber, Kurt, Hulin, Ivan, Ivanusa, Mario, Krittayaphong, Rungroj, Kuo, Chi-Tai, Lau, Chu-Pak, Lyusov, Victor A., Marinskis, Germana, Márquez, Manlio, Masic, Izet, Pinho Moreira, Luiz Felipe, Mrochek, Alexander, Oganov, Rafael G., Raev, Dimitar, Rogava, Mamanti, Rødevand, Olaf, Sansoy, Vedat, Shimokawa, Hiroaki, Shumakov, Valentin A., Tajer, Carlos Daniel, Van Der Wall, Ernst E., Stefanadis, Christodoulo, Videbæk, Jørgen, Lüscher, Thomas F., Repositório da Universidade de Lisboa, Editors' Network European Society of Cardiology Task Force, Sinica AC, Christer Höglund C, Fernando Alfonso, Adam Timmi, Fausto Pinto, Giuseppe Ambrosio, Hugo Ector, Piotr Kulakowski, Panos Antoniade, Mansoor Ahmad, Eduard Apetrei, Kaduo Arai, JeanYves Artigou, Michael Aschermann, Michael Bohm, Leonardo Bolognese, Raffaele Bugiardini, Ariel Cohen, Istvan Ede, Joseph Elia, Javier Galeano, Eduardo Guarda, Habib Haouala, Magda Hera, Christer Hoglund, Kurt Huber, Ivan Hulin, Mario Ivanusa, Rungroj Krittayaphong, ChiTai Kuo, ChuPak Lau, Victor Lyusov, Germanas Marinski, Manlio Mrquez, Izet Masic, Luiz Moreira, Alexander Mrochek, Rafael Oganov, Dimitar Raev, Mamanti Rogava, Olaf Rdevand, Vedat Sansoy, Hiroaki Shimokawa, Valentin Shumakov, Carlos Tajer, Ernst Wall, Christodoulos Stefanadi, Jrgen Videbk, and Thomas Luscher

Subjects
Journal, lcsh:Diseases of the circulatory (Cardiovascular) system, MEDICAL JOURNALS, CLINICAL-TRIALS, PHARMACEUTICAL-INDUSTRY, COMPETING INTERESTS, BIOMEDICAL-RESEARCH, EDITORS NETWORK, DRUG-INDUSTRY, PUBLICATION, ASSOCIATION, SPONSORSHIP, конфликт интересов, conflicts of interest, disclosure, editorial ethics, journals, Periodicals, Surveys and Questionnaires, Credibility, Conflict of interest, Publishing/ethics, Cardiology and Cardiovascular Medicine, Pharmacology (medical), Societies, Medical, раскрытие, General Environmental Science, Pharmaceutical industry, Disclosures, Editorial ethics, Journals, Medicine (all), Data Collection, Editorial ethic, General Medicine, Europe, conflict of interest, disclosure, editorial ethics, journals, Disclosure, Authorship, Cardiology, Drug Industry, Periodicals as Topic, Research Support as Topic, Conflict of Interest, Editorial Policies, medicine.medical_specialty, журналы, редакционная этика, MEDLINE, Library science, RM1-950, Truth Disclosure, Special Article, conflicts of interest, Cross-Sectional Studies, Humans, Political science, Medical, Internal medicine, medicine, Diseases of the circulatory (Cardiovascular) system, Conflict of interest, Disclosure, Editorial ethics, Journals, Closure (psychology), Drug industry, Competing interests, business.industry, lcsh:RM1-950, Conflict of interest, disclosures, editorial ethics, journals, Transparency (behavior), lcsh:Therapeutics. Pharmacology, lcsh:RC666-701, RC666-701, sukob interesa, prijavljivanje sukoba interesa, urednička etika, časopisi, General Earth and Planetary Sciences, Therapeutics. Pharmacology, cardiology, conflict of interest, Europe, interpersonal communication, medical society, publication, publishing, Societies, business
Abstract

Biomedicinski časopisi prijavljivanje sukoba interesa (COI ・prema engl. conflict of interest) koriste kako bi jamčili vjerodostojnost i transparentnost znanstvenih postupaka. Međutim,časopisi se s prijavljivanjem COI ne bave niti sistematski niti dosljedno. Nedavna zajednička nastojanja urednika su utrla put prema implementaciji jedinstvenih načina prijave COI. Ovaj dokument prža sveobuhvatni urednički stav o klasičnim problemima vezanim za COI. Raspravlja se o novim uvidima u trenutne COI smjernice i prakse nacionalnih kardiovaskularnih časopisa Europskog kardiološkog društva koji su izvedeni iz presječnog anketnog istraživanja primjenom standardiziranog upitnika., Disclosure of potential conflicts of interest (COI) is used by biomedical journals to guarantee credibility and transparency of the scientific process. COI disclosure, however, is not systematically nor consistently dealt with by journals. Recent joint editorial efforts paved the way towards the implementation of uniform vehicles for COI disclosure. This paper provides a comprehensive editorial perspective on classical COI-related issues. New insights into current COI policies and practices among European Society of Cardiology national cardiovascular journals, as derived from a cross-sectional survey using a standardised questionnaire, are discussed.

Published
2012

3. Outcome of patients on oral anticoagulation undergoing coronary artery stenting: Data from discharge to 12 months in the warfarin and coronary stenting (WAR-STENT) registry

Author

Andrea, Rubboli, Francesco, Saia, Alessandro, Sciahbasi, Maria Letizia, Bacchi-Reggiani, Luigi, Steffanon, Carlo, Briguori, Paolo, Calabrò, Cataldo, Palmieri, Andrea, Rizzi, Ferdinando, Imperadore, Giuseppe M, Sangiorgi, Marco, Valgimigli, Giuseppe, Carosio, Giuseppe, Steffenino, Marcello, Galvani, Giuseppe, Di Pasquale, Luigi, La Vecchia, Aldo P, Maggioni, Leonardo, Bolognese, Paolo, Rubartelli, Rubboli, Andrea, Saia, Francesco, Sciahbasi, Alessandro, Bacchi-Reggiani, Maria Letizia, Steffanon, Luigi, Briguori, Carlo, Calabrò, Paolo, Palmieri, Cataldo, Rizzi, Andrea, Imperadore, Ferdinando, Sangiorgi, Giuseppe M, Valgimigli, Marco, Carosio, Giuseppe, Steffenino, Giuseppe, Galvani, Marcello, Di Pasquale, Giuseppe, La Vecchia, Luigi, Maggioni, Aldo P, and Bolognese, Leonardo

Subjects
Ticlopidine, Aspirin, Administration, Oral, Settore MED/11 - Malattie dell'Apparato Cardiovascolare, Drug-Eluting Stents, Hemorrhage, Databases, Bibliographic, Clopidogrel, Treatment Outcome, percutaneous coronary intervention, oral anticoagulation, stent, Drug Therapy, Combination, cardiovascular diseases, Prospective Studies, Registries, Warfarin, Angioplasty, Balloon, Coronary, circulatory and respiratory physiology, Follow-Up Studies
Abstract

To obtain further, and more focused, information on the efficacy and safety of the antithrombotic regimens, including triple therapy (TT) of warfarin, aspirin, and clopidogrel; dual therapy (DT) of warfarin and single antiplatelet agent (aspirin or clopidogrel); and dual-antiplatelet therapy (DAPT) of aspirin and clopidogrel, prescribed to patients on oral anticoagulation (OAC) undergoing percutaneous coronary intervention with stent (PCI-S).The true efficacy and safety of TT, DT, and DAPT in OAC patients undergoing PCI-S is largely undefined.We analyzed the database of the prospective, multicenter WARfarin and coronary STENTing (WAR-STENT) registry (ClinicalTrials.gov identifier NCT00722319), only including the post-discharge period.Of the 401 patients discharged alive from index hospitalization, 339 (85%), 20 (5%), and 42 (10%) were prescribed TT, DT, and DAPT, respectively. Throughout a mean follow-up of 368.3 ± 22.8 days, major adverse cardiovascular events (MACE) (including cardiovascular death, myocardial infarction, repeat revascularization, stent thrombosis, and thromboembolism), total bleeding, major bleeding, and combination of MACE plus total bleeding were comparable across the three treatment groups. The absolute rate of major bleeding with TT was 4%. The antithrombotic treatment actually ongoing at major bleeding was TT in 44%, DT in 50%, and DAPT in 6% of cases.In the real-world population of OAC patients undergoing PCI-S in the WAR-STENT registry, the three antithrombotic regimens of TT, DT, and DAPT showed comparable efficacy and safety. Due to several limitations, our data cannot be considered conclusive in confuting the current recommendations to prescribe TT. Further properly designed and sized studies are warranted.

Catalog

Books, media, physical & digital resources
See catalog results